New insulin set aims to last a full week – no more Every-Other-Day changes?
NCT ID NCT06273124
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tested a new insulin infusion set designed to be worn for up to 7 days instead of the usual 2-3 days. 260 adults with type 1 diabetes used the set at home for 12 wear periods. The goal was to see if the set could safely deliver insulin for a full week without causing high blood sugar or other problems.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
SteadiSet Extended Wear Infusion Set (a device that delivers insulin continuously for up to 7 days)
What this could lead to
If successful, this could allow people with type 1 diabetes to change their insulin infusion set only once a week instead of every 2-3 days, making daily management easier.
What could go wrong
This is a completed study, but results are not yet published. The device may not last the full 7 days for everyone, and there is a risk of high blood sugar or ketones if it fails.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE1DIABETES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Barbara Davis Center
Aurora, Colorado, 80045, United States
-
Endocrine Research Solutions
Roswell, Georgia, 30076, United States
-
Henry Ford Health System
Detroit, Michigan, 48202, United States
-
Hoag Memorial Hospital Presbyterian
Newport Beach, California, 92663, United States
-
Icahn School of Medicine at Mt. Sinai
New York, New York, 10029, United States
-
International Diabetes Center - HealthPartners Institute
Minneapolis, Minnesota, 55416, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Mayo Clinic
Rochester, Minnesota, 55905, United States
-
Northwestern University
Evanston, Illinois, 60208, United States
-
Rainier Clinical Research Center
Renton, Washington, 98057, United States
-
Rocky Mountain Clinical Research
Idaho Falls, Idaho, 83404, United States
-
SUNY Upstate Medical University
Syracuse, New York, 13210, United States
-
Stanford University
Stanford, California, 94305, United States
-
Texas Diabetes and Endocrinology
Austin, Texas, 78731, United States
-
University of Washington
Seattle, Washington, 98109, United States